Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LPP CRISPR/Cas9 KO Plasmid (h): sc-406769
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LPP CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LPP genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LPP Antibody (8B3A11): sc-101434
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LPP CRISPR/Cas9 KO Plasmid (h) | sc-406769 | 20 µg | $397.00 |
Overview
LPP (lipoma‑preferred partner) encodes a LIM domain–containing adaptor protein that localizes to focal adhesions and cell–cell junctions, where it couples cytoskeletal tension to transcriptional responses. Through interactions with actin-associated proteins and signaling hubs, LPP contributes to integrin-linked adhesion dynamics, mechanotransduction, and regulation of cell migration and invasion programs. It is also implicated in nuclear shuttling and modulation of gene expression downstream of adhesion-dependent pathways. Altered LPP expression or rearrangement has been reported in contexts including mesenchymal tumors and metastatic progression, supporting its utility as a target for studying adhesion-regulated oncogenic phenotypes.
LPP CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the LPP gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the LPP together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the LPP open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LPP protein expression.
This CRISPR knockout system enables efficient generation of LPP-deficient cell models for investigation of LPP signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting LPP exon(s) critical for LPP function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple LPP genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LPP CRISPR/Cas9 KO Plasmid (h) and LPP CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the LPP locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LPP HDR Plasmid (h) and LPP HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by LPP homology arms to support homology-directed repair at defined LPP target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.